Safety of Azathioprine Therapy Adjusted to Thiopurine Methyltransferase Activity in the Treatment of Infantile Atopic Dermatitis. Report on 7 Cases

Martel, Rosa; Melwani, P.; Islas, Diana; Peñate, Yeray; Borrego, Leopoldo

doi:10.1016/s1578-2190(10)70664-8

Search citation statements

Order By: Relevance

Paper Sections

Select...

Immunosuppressive Agents1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2011

2023

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

(1 citation statement)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Improvements occur within 2–3 months with an indeterminate duration ( 87 , 88 ). Serum thiopurine S-methyltransferase activity allows for safer use of AZA in children ( 88 , 89 ). When this is unavailable, half the standard dose (2–3 mg/kg/day) for 4–6 weeks is followed by a full dose ( 53 , 70 , 84 ).…”

Section: Immunosuppressive Agentsmentioning

confidence: 99%

Anti-inflammatory and biologic drugs for atopic dermatitis: a therapeutic approach in children and adolescents

Caffarelli,

Giannetti,

Giannì

et al. 2023

Front. Med.

View full text Add to dashboard Cite

Atopic dermatitis (AD) is a chronic inflammatory disease with a heterogeneous pathogenesis correlated with dysregulation of the immune system and a prevalence of the T2-mediated immune pathway. Recent understanding of the pathogenesis of AD has allowed the development of new drugs targeting different mechanisms and cytokines that have changed the treatment approach. The aim of this review is to update knowledge on the standard of care and recent advancements in the control of skin inflammation. In light of recent guidelines, we report on the clinical efficacy of novel treatments, with special attention to situations where biologics and small molecules are involved.

show abstract